Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12’s Effectiveness in Treating Psoriasis
Artelo Biosciences (Nasdaq: ARTL) has published new research in the Journal of Investigative Dermatology demonstrating the effectiveness of ART26.12, their FABP5 inhibitor, in treating psoriasis. The study shows that ART26.12, an orally active small-molecule drug, achieved comparable results to immunomodulatory drugs in both in vitro and in vivo psoriasis models.
The research highlights that FABP5, first discovered in psoriasis tissue in the 1990s, is highly expressed in skin and immune cells and plays a important role in skin cell homeostasis. Pre-clinical studies suggest ART26.12 may offer a less costly and safer treatment approach for psoriasis compared to existing options.
The company has completed enrollment for its Phase 1 Single Ascending Dose study of ART26.12 in healthy volunteers, with data expected to be announced in the current quarter.
Artelo Biosciences (Nasdaq: ARTL) ha pubblicato una nuova ricerca sul Journal of Investigative Dermatology che dimostra l'efficacia di ART26.12, il loro inibitore di FABP5, nel trattamento della psoriasi. Lo studio evidenzia che ART26.12, un farmaco orale a piccola molecola, ha ottenuto risultati comparabili a quelli dei farmaci immunomodulatori sia in modelli di psoriasi in vitro che in vivo.
La ricerca sottolinea che FABP5, scoperto per la prima volta nei tessuti psoriasici negli anni '90, è altamente espresso nelle cellule della pelle e del sistema immunitario e svolge un ruolo fondamentale nell'omeostasi delle cellule cutanee. Studi preclinici suggeriscono che ART26.12 potrebbe rappresentare un trattamento meno costoso e più sicuro rispetto alle opzioni attuali per la psoriasi.
L'azienda ha completato il reclutamento per lo studio di Fase 1 a dose singola ascendente di ART26.12 su volontari sani, con i dati che saranno annunciati nel trimestre in corso.
Artelo Biosciences (Nasdaq: ARTL) ha publicado una nueva investigación en el Journal of Investigative Dermatology que demuestra la eficacia de ART26.12, su inhibidor de FABP5, en el tratamiento de la psoriasis. El estudio muestra que ART26.12, un fármaco oral de pequeña molécula, logró resultados comparables a los de los medicamentos inmunomoduladores en modelos de psoriasis tanto in vitro como in vivo.
La investigación destaca que FABP5, descubierto por primera vez en tejidos de psoriasis en los años 90, se expresa en gran medida en células de la piel y del sistema inmunológico, y desempeña un papel importante en la homeostasis de las células cutáneas. Los estudios preclínicos sugieren que ART26.12 podría ofrecer un tratamiento más seguro y menos costoso para la psoriasis en comparación con las opciones existentes.
La compañía ha completado la inscripción para su estudio de Fase 1 de dosis única ascendente de ART26.12 en voluntarios sanos, y se espera que los datos se anuncien en el trimestre actual.
Artelo Biosciences (나스닥: ARTL)는 Journal of Investigative Dermatology에 자사의 FABP5 억제제인 ART26.12가 건선 치료에 효과적임을 입증한 새로운 연구 결과를 발표했습니다. 연구에 따르면 경구용 저분자 약물인 ART26.12는 시험관 내(in vitro) 및 생체 내(in vivo) 건선 모델에서 면역조절제와 유사한 효과를 보였습니다.
이 연구는 1990년대 건선 조직에서 처음 발견된 FABP5가 피부와 면역 세포에서 높게 발현되며 피부 세포 항상성 유지에 중요한 역할을 한다는 점을 강조합니다. 전임상 연구 결과 ART26.12는 기존 치료제보다 비용이 적게 들고 안전한 건선 치료법이 될 가능성이 있습니다.
회사는 건강한 지원자를 대상으로 한 ART26.12의 1상 단회 증량 연구 등록을 완료했으며, 관련 데이터는 이번 분기에 발표될 예정입니다.
Artelo Biosciences (Nasdaq : ARTL) a publié une nouvelle étude dans le Journal of Investigative Dermatology démontrant l'efficacité de ART26.12, leur inhibiteur de FABP5, dans le traitement du psoriasis. L'étude montre que ART26.12, un médicament oral à petite molécule, a obtenu des résultats comparables à ceux des médicaments immunomodulateurs dans des modèles de psoriasis in vitro et in vivo.
La recherche souligne que FABP5, découvert pour la première fois dans les tissus psoriasiques dans les années 1990, est fortement exprimé dans les cellules de la peau et du système immunitaire, jouant un rôle important dans l'homéostasie des cellules cutanées. Des études précliniques suggèrent que ART26.12 pourrait offrir une approche thérapeutique moins coûteuse et plus sûre pour le psoriasis par rapport aux options existantes.
L'entreprise a terminé le recrutement pour son étude de phase 1 à dose unique ascendante d'ART26.12 chez des volontaires sains, les données devant être annoncées au cours du trimestre en cours.
Artelo Biosciences (Nasdaq: ARTL) hat eine neue Studie im Journal of Investigative Dermatology veröffentlicht, die die Wirksamkeit von ART26.12, ihrem FABP5-Inhibitor, bei der Behandlung von Psoriasis belegt. Die Studie zeigt, dass ART26.12, ein oral wirksames niedermolekulares Medikament, in vitro und in vivo vergleichbare Ergebnisse zu immunmodulatorischen Medikamenten erzielte.
Die Forschung hebt hervor, dass FABP5, erstmals in den 1990er Jahren in Psoriasis-Gewebe entdeckt, in Haut- und Immunzellen stark exprimiert wird und eine wichtige Rolle bei der Homöostase der Hautzellen spielt. Präklinische Studien deuten darauf hin, dass ART26.12 eine kostengünstigere und sicherere Behandlungsoption für Psoriasis im Vergleich zu bestehenden Therapien bieten könnte.
Das Unternehmen hat die Rekrutierung für seine Phase-1-Studie mit einmalig steigender Dosierung von ART26.12 bei gesunden Freiwilligen abgeschlossen, und die Daten sollen im laufenden Quartal veröffentlicht werden.
- Successful completion of Phase 1 trial enrollment
- Demonstrated efficacy comparable to existing treatments in preclinical studies
- Potential for better safety profile based on pre-clinical data
- Publication in prestigious peer-reviewed journal validates research
- Still in early clinical stages with no human efficacy data yet
- Faces competition from established immunomodulatory drugs
Insights
Artelo reports dual progress: published research showing ART26.12's efficacy in psoriasis models and completed Phase 1 enrollment with results expected soon.
Artelo Biosciences has achieved two key milestones for their FABP5 inhibitor ART26.12. First, they've published research in the peer-reviewed Journal of Investigative Dermatology demonstrating that ART26.12 showed positive effects in both in vitro and in vivo psoriasis models. According to the article, these effects were "comparable to immunomodulatory drugs with known serious adverse events," suggesting potential differentiation on the safety profile.
Second, they've completed enrollment in their Phase 1 Single Ascending Dose study in healthy volunteers, with data announcements expected this quarter. Phase 1 studies typically focus on safety, tolerability, and pharmacokinetics rather than efficacy in patient populations.
The scientific rationale appears grounded in established research, as the article notes FABP5 was first discovered in psoriasis tissue in the early 1990s. The lead author highlighted that pre-clinical studies and literature reviews suggest a "low toxicological risk" for ART26.12, important since current psoriasis treatments often have significant side effect profiles.
As an orally active small molecule, ART26.12 represents a different approach compared to many psoriasis treatments. If the favorable preclinical safety profile translates to humans, this could potentially address an important medical need, though clinical development is still in early stages.
The upcoming Phase 1 data will provide critical initial information about ART26.12's safety profile in humans, representing an important de-risking milestone in the development pathway.
ART26.12 Phase 1 in healthy volunteers completes enrollment with clinical data announcement expected this quarter
SOLANA BEACH, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced new research published in the peer-reviewed Journal of Investigative Dermatology describing the positive effects of ART26.12 in both in vitro and in vivo psoriasis models, showing results comparable to immunomodulatory drugs with known serious adverse events.
The research article, titled “ART26.12, A FATTY ACID-BINDING PROTEIN 5 INHIBITOR, SHOWS EFFICACY IN PRECLINICAL PSORIASIS MODELS,” highlights ART26.12, Artelo’s orally active, small-molecule inhibitor of Fatty Acid Binding Protein 5 (FABP5) and its potential ability to treat psoriasis.
George Warren, PhD, Lead Author and Principal Scientist at Artelo, said, “We are excited to share the results on this novel target in psoriasis. Our findings demonstrate that ART26.12 has effects comparable to powerful immunomodulators, while its unique pharmacology leads to a significantly distinct expression of proteins and lipids in the skin.”
FABP5, sometimes referred to as epidermal FABP, was first discovered in psoriasis tissue in the early 1990s. It is highly expressed in skin and immune cells and plays a key role in skin cell homeostasis. FABP5 is upregulated in numerous dermatological conditions, promoting inflammation and correlating with disease severity.
Dr. Warren added, “Pre-clinical IND-enabling studies with ART26.12, supported by a literature review of greater than 300 studies examining FABP inhibition, imply a low toxicological risk for ART26.12, which, if borne out in clinical studies, suggest FABP5 inhibition with an orally delivered small molecule may be an attractive, less costly, and safer approach for treating this debilitating chronic disease.”
A Phase 1 Single Ascending Dose study in healthy volunteers with ART26.12 has completed enrollment with data announcements expected this quarter.
About ART26.12
ART26.12, Artelo’s lead FABP5 inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. Data from the first Phase 1 trial with ART26.12 is anticipated in Q2 2025. The initial clinical development planned is for chemotherapy-induced peripheral neuropathy (CIPN). FABPs are a family of intracellular proteins that chaperone lipids important to normal cellular function. FABP is overexpressed and associated with abnormal lipid signaling in several pathologies. In addition to ART26.12 in CIPN, Artelo’s extensive library of small molecule inhibitors of FABPs has shown therapeutic promise for the treatment of certain cancers, neuropathic and nociceptive pain, psoriasis, and anxiety disorders.
About Psoriasis
Psoriasis is a chronic autoimmune condition that accelerates the production of skin cells, leading to the formation of red, scaly patches. Affecting about 2–
About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the Company applies leading-edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and X: @ArteloBio.
Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.
Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com
FAQ
What are the key findings of Artelo Biosciences' ART26.12 psoriasis research?
When will ARTL release the Phase 1 clinical trial results for ART26.12?
How does Artelo's ART26.12 differ from current psoriasis treatments?
What is the significance of FABP5 in psoriasis treatment?
